Cancer Treatment Tolerability Consortium

The NCI Cancer Moonshot Tolerability Consortium is a consortium of multidisciplinary teams that is developing new methods for analyzing patient-reported outcomes in the setting of cancer clinical trials. These methods will better define patient tolerability to cancer treatment.

The tolerability of cancer treatments is a critical element of reducing suffering and death from this disease. In addition to the acute toxicities of treatment, long-term and chronic side effects can both decrease a patient’s ability to complete treatment and greatly affect their quality of life.

This consortium seeks to expand upon the use and reach of the PRO-CTCAE and other PRO instruments that can inform symptomatic toxicities and their impacts, as well as develop more methods to analyze and report.

Read more About the Tolerability Consortium.

Consortium Organization

  • Steering Committee
  • Members
  • NCI/FDA Stakeholders

Learn more about the Consortium Organization

Working Groups

  • GP5
  • Standardization Working Group
  • Common Data Elements

See the Working Groups

Resources and Tools

  • Selected Scoring and Summary Measures
  • Color Schemes
  • Other Resources

Learn more about the Tolerability Consortium's
Resources and Tools


View the Publications


View the Presentations